Drug Profile
Recombinant birch pollen allergoid (folding variant) - Allergopharma
Alternative Names: rBet v1 - folding variant; rBet v1-FVLatest Information Update: 15 May 2015
Price :
$50
*
At a glance
- Originator Biomay
- Developer Allergopharma
- Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 01 Sep 2011 Allergopharma completes a phase II trial in Seasonal allergic rhinitis in Germany (NCT01490411)
- 24 Aug 2010 Phase II development is ongoing in Sweden
- 24 Aug 2010 Phase III development is ongoing in Germany